Human/Monkey/Canine Osteopontin（OPN） enzyme-linked immunoassay kit
| Specification | 96 Test |
|---|---|
| Sensitivity | 0.04 ng/ml (50 μl)；0.12 ng/ml (10 μl) |
| Standard Curve Range | 0.31~20 ng/ml |
| Standard Curve Gradient | 7 Points |
| Number of Incubations | 2 |
| Detectable sample | Liquid phase sample of soluble substances. For example: serum, plasma, cell culture supernatant, tissue grinding liquid, etc. |
| Sample Volume | 50 μl/10 μl |
| Type | Fully Ready-to-Use |
| Operation Duration | 120min |
| ng/ml | O.D. | Average | Corrected | |
|---|---|---|---|---|
| 0.00 | 0.0246 | 0.0244 | 0.0245 | |
| 0.31 | 0.0543 | 0.0502 | 0.0523 | 0.0278 |
| 0.63 | 0.0937 | 0.0866 | 0.0902 | 0.0657 |
| 1.25 | 0.2017 | 0.1903 | 0.1960 | 0.1715 |
| 2.50 | 0.5132 | 0.5027 | 0.5080 | 0.4835 |
| 5.00 | 1.0570 | 0.9935 | 1.0253 | 1.0008 |
| 10.00 | 1.9270 | 1.8780 | 1.9025 | 1.8780 |
| 20.00 | 3.0580 | 2.9620 | 3.0100 | 2.9855 |
Precision
| Intra-assay Precision | Inter-assay Precision | |||||
| Sample Number | S1 | S2 | S3 | S1 | S2 | S3 |
| 22 | 22 | 22 | 6 | 6 | 6 | |
| Average(ng/ml) | 0.42 | 2.09 | 6.22 | 0.51 | 2.10 | 6.03 |
| Standard Deviation | 0.02 | 0.09 | 0.48 | 0.02 | 0.10 | 0.37 |
| Coefficient of Variation(%) | 4.9 | 4.5 | 7.7 | 4.3 | 4.7 | 6.1 |
Intra-assay Precision (Precision within an assay) Three samples of known concentration were tested twenty times on one plate to assess intra-assay precision.
Inter-assay Precision (Precision between assays) Three samples of known concentration were tested six times on one plate to assess intra-assay precision.
Spike Recovery
The spike recovery was evaluated by spiking 3 levels of human OPN into health human serum sample. The un-spiked serum was used as blank in this experiment.
The recovery ranged from 83% to 117% with an overall mean recovery of 108%.
Sample Values
| Sample Matrix | Sample Evaluated | Range (ng/ml) | Detectable (%) | Mean of Detectable (ng/ml) |
|---|---|---|---|---|
| Human Serum | 30 | 1.1-6.74 | 100 | 3.97 |
Serum/Plasma – Thirty samples from apparently healthy volunteers, two samples from healthy monkeys and five samples from healthy canines were evaluated for the presence of human OPN in this assay. No medical histories were available for the donors.
n.d. = non-detectable. Samples measured below the sensitivity are considered to be non-detectable.
Product Data Sheet
Background: OPN
Osteopontin (OPN), also known as bone sialoprotein (BSP), is a secreted SIBLING family protein that can be variably modified by O- and N-glycosylation, sulfation, phosphorylation, and transglutamination. OPN is widely expressed and is prominent in mineralized tissues. It inhibits bone mineralization and kidney stone formation and promotes inflammation, cell ad¬hesion, and migration. Its expression is upregulat¬ed during inflammation, obesity, atherosclerosis, cancer, and tissue damage and contributes to the pathophysiology of these conditions. The central region of OPN contains RGD and non-RGD binding sites for multiple integrins. Adjacent to the RGD motif is the sequence SLAYGLR (SVVYGLR in human) which serves as a cryptic binding site for additional integrins: it is masked in full length OPN but is exposed following OPN cleavage by multiple proteases in tumors and sites of tissue injury.
